Immunome IMNM Purchases Of In Process Research And Development Assets Including Payments Owed Upon Achievement Of Development Milestones In Accounts Payable And Accrued Expenses
Purchases Of In Process Research And Development Assets Including Payments Owed Upon Achievement Of Development Milestones In Accounts Payable And Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept imnm:PurchasesOfInProcessResearchAndDevelopmentAssetsIncludingPaymentsOwedUponAchievementOfDevelopmentMilestonesInAccountsPayableAndAccruedExpenses.
The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunome's purchases of in process research and development assets including payments owed upon achievement of development milestones in accounts payable and accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunome's purchases of in process research and development assets including payments owed upon achievement of development milestones in accounts payable and accrued expenses?
- Immunome (IMNM) reported purchases of in process research and development assets including payments owed upon achievement of development milestones in accounts payable and accrued expenses of $986K in Q1 2026.
- What does purchases of in process research and development assets including payments owed upon achievement of development milestones in accounts payable and accrued expenses mean?
- This captures the total investment in in-process research and development assets, including both cash payments and obligations accrued for future milestone achievements. It provides a comprehensive view of the total committed capital toward external innovation. This metric helps investors track the full scope of R&D investment beyond immediate cash outlays.